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Abstract
Background: The significance of carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7)
expression in gastric carcinoma and precancerous lesions and its correlation with CEA expression has rarely been
previously investigated.
Methods: CEACAM7 and CEA expression was detected by immunohistochemistry in consecutive sections of 345
subjects with gastric carcinoma and precancerous lesions. Laser confocal analysis was performed to determine
CEACAM7 and CEA localization. Correlation between CEACAM7 and CEA expression with clinicopathological
parameters was statistically analyzed.
Results: CEACAM7 expression correlated with pathologic grading (P = 0.006), Lauren’s classification (P = 0.023), and
CEA expression (Spearman R = 0.605, P < 0.001) in gastric carcinoma. CEACAM7 co-localized with CEA
predominantly in the cytoplasmic membrane of cancerous cells. CEA expression was correlated with lymph node
metastasis (P = 0.031). CEACAM7 and CEA expression increased progressively from precursor lesions to gastric
carcinomas. A combination of CEACAM7 and CEA expression was determined to be an independent predictor for
patients with gastric carcinoma by multivariate analysis (P = 0.001).
Conclusions: CEACAM7 expression correlates with tumor differentiation and CEA expression in gastric carcinoma.
CEACAM7 and CEA expression may synergistically promote gastric carcinogenesis. Combined CEACAM7 and CEA
expression analysis can be a useful postoperative predictor for patients with gastric carcinoma.
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Background
I n - d e p t hk n o w l e d g eo ft h eg e n o t y p i ca n dp h e n o t y p i c
characteristics of gastric carcinoma and precancerous
lesions is extremely important for preventing their
development, curtailing their progression to a higher
grade tumor once they develop, and providing prognos-
tic information. Gastric carcinomas have generally been
divided into intestinal-type and diffuse-type by Lauren
[1]. The intestinal-type cancer was thought to display a
predominantly intestinal phenotype because it is pre-
ceded by a precancerous stage characterized by the
sequential steps of atrophic gastritis, intestinal metapla-
sia, intraepithelial neoplasia (GIN), and intramucosal
carcinoma [2,3]. GIN is recognized as an important pre-
cancerous lesion, and is categorized as either high- or
low-grade according to both the Vienna [4] and WHO
[5] classifications. It has been reported that the predo-
minant histologic type may change from the differen-
tiated to the undifferentiated type as the tumors
progress [6]. Ohkura, et al alsor e p o r t e dt h a th i s t o l o g i c
diversity increased as the gastric carcinomas grew or
invaded the submucosa [7]. Recent progress in molecu-
lar biology has shown that the phenotypic diversity of
tumors is associated with a corresponding diversity in
gene expression [8-10]. Changes in expression of tumor
specific biomarkers in precancerous lesions and various
differentiated gastric carcinomas may help us
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neity and the underlying molecular mechanism.
The carcinoembryonic antigen (CEA) family of genes
has been shown to be expressed in a variety of epithelial
derived neoplasms [11], and their functional deregula-
tion has been shown to promote metastases in animal
models[12]. One particular CEA gene family member,
the CEA cellular adhesion molecule-7 (CEACAM-7),
regulates normal cellular differentiation [11]. Deregula-
tion of CEACAM-7 expression has been shown to occur
early in colorectal oncogenesis; decreased CEACAM-7
expression was shown in adenomas, hyperplastic polyps,
and aberrant crypt foci [11,13]. CEA, another member
of the carcinoembryonic antigen family, represents a
tumor marker used widely in the management of color-
ectal cancer [14-16]. Increased CEA levels were the first
identified indicator of recurrent disease in 81% [17] and
89% [18] of colorectal cancer patients. Both mesenteric
and peripheral levels of CEA were higher in neoplasms
with venous involvement, large diameter, and advanced
stages of colorectal carcinoma [19]. Increased CEA
values have also been reported for other epithelial
malignancies, such as those of the breast, lung, and pan-
creas [20].
To date, little information is available on CEACAM7
expression in gastric nonneoplastic and neoplastic
lesions. One study reports that CEACAM7 mRNA levels
were up-regulated in cancerous gastric epithelial cells
[21]. However, the significance of CEA and CEACAM7
expression in precancerous lesions of gastric carcinoma
is poorly understood. Besides, the relationship between
CEACAM7 and CEA is unclear, although they belong to
the same CEACAM family.
In this study, we investigated the correlation between
CEACAM7 and CEA expression, and their relationship
to various clinicopathological features in gastric carci-
noma, including patient survival. We compared the
expression patterns of CEACAM7 and CEA systemati-
cally in normal mucosa, chronic atrophic gastritis, gas-
tric intraepithelial neoplasia (GIN), and carcinomas of
the stomach with consecutive tissue microarray (TMA)
sections. To our knowledge, this is the first immunohis-
tochemical study of CEACAM7 expression in gastric
carcinoma and precancerous lesions.
Methods
Patients
The study included 345 patients, including 145 patients
with gastric carcinoma who underwent primary surgical
resection between 2006 and 2009 at the Xijing Hospital
of Forth Military Medical University (Xi’an, China), 100
patients with intraepithelial neoplasms (55 low-grade
and 45 high-grade), 50 patients with chronic atrophic
gastritis, and 50 patients with normal gastric mucosa.
The 200 patients with nonneoplastic and precancerous
lesions had received a gastric endoscopic check and
biopsy between 2008 and 2010 at the Xijing Hospital.
All diagnoses, including differentiation status, were
made based on the Pathology and Genetics Tumors of
Digestive System by three pathologists [22]. GIN is cate-
gorized as either high- or low-grade according to both
the Vienna [4] classifications. Follow-up was performed
on the 145 patients with gastric carcinoma for survival
analysis. These patients underwent subtotal gastrectomy
with D2 lymph node dissection at Xijing Hospital from
2006 to 2009. The mean age was 56.4 years (range, 32-
74 years). All patients received postoperative chemother-
apy using a fluorouracil-based regimen. No patients
received preoperative chemotherapy or underwent
radiotherapy. Follow-up was performed on patients from
the date of surgery until either the date of death or
March 30, 2011, resulting in follow-up periods ranging
from 5 to 67 months (mean, 31 months). Those cases
lost to follow-up or those who died of a cause other
than gastric cancer were regarded as censored data for
the analysis of survival rates. In all cases, informed con-
sent was obtained for the use of resected tumor speci-
mens. This study was approved by the Moral and
Ethical Committee of the Xijing Hospital of Forth Mili-
tary Medical University.
Tissue Microarrays
Tissues of gastric carcinoma or precancerous lesions
were made into tissue micro-arrays by Tissue Microar-
rayer (Beecher Instruments, Silver Spring, USA ™),
according to the technique of Kononen et al [23].
Briefly, core tissue biopsies (2 mm in diameter) were
taken from individual paraffin-embedded tissues (donor
blocks) and arranged in a new recipient paraffin block
( t i s s u ea r r a yb l o c k )u s i n gat r e p h i n ea p p a r a t u s .T h e
staining results of the different areas in these tissue
array blocks showed excellent agreement. One core was
chosen from each case for analysis. We defined an ade-
quate case as a tumor that occupied 10% of the core
area.
Primary antibodies for immunohistochemistry
Mouse anti-human CEACAM7 antibody [BAC2]
(ab26281) and Rabbit Anti-human CEA antibody (ab-
15157) was all purchased from Abcam plc. (Cambridge,
UK).
Immunohistochemistry
Immunohistochemistry was performed on 4-lm-thick,
routinely processed, paraffin sections in series. Briefly,
after baking on a panel at 60°C for an hour, the paraffin
embedded, formalin fixed tissue samples were deparaffi-
nized with xylene and rehydrated through gradient
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quenched by 3% (vol/vol) hydrogen peroxide in metha-
nol for 10 minutes, followed by three 3-minute washes
with phosphate buffered saline (PBS). This was followed
by a step of antigen retrieval. The slides were immersed
in 0.01 mol/l citrate buffer solution (pH 6.0) and placed
in a microwave oven for 30 min. After a wash in 0.01
mol/l of phosphate-buffered saline (PBS, pH 7.4), The
sections were then blocked with 10% (vol/vol) normal
goat serum in PBS for 30 minutes followed by incuba-
tion in a moist chamber at 4 overnight with the primary
antibody to CEACAM7 (1:100, ab26281, Abcam) or
CEA 1:10, ab-15157, Abcam) diluted in PBS containing
1% (wt/vol) bovine serum albumin (BSA). Negative con-
trols were performed by replacing the primary antibody
with pre-immune mouse serum. After three 3-minute
washes with PBS, the sections were treated with second
anti-mouse antibody (PV-6002, Santa Cruz) for 30 min-
utes at room temperature followed by additional three
3-minute washes with PBS. Reaction product was visua-
lized with diaminobenzidine (DAB, ZLI-9032, ZSGB.
Beijing, China) at room temperature for 2 min. After
being counterstained with Harris hematoxylin (ZLI-
9039, ZSGB. Beijing, China) for 3 min, and rinsed with
tap water, the sections were immediately dehydrated by
sequential immersion in gradient ethanol and xylene,
and mounted with pernount and cover slips. Images
were obtained under a light microscope (Olympus
BX51, Olympus, Japan) equipped with a DP70 digital
camera.
Evaluation of Staining
For evaluation of cell staining, sections were examined
by two independent pathologists without prior knowl-
edge of the clinicopathological status of the specimens.
Expression of CEACAM7 and CEA was evaluated
according to the ratio of positive cells per specimen (R)
and staining intensity (I). The ratio of positive cells per
specimen was scored 0 for staining of < 1%, 1 for stain-
ing of 2 to 25%, 2 for staining of 26 to 50%, 3 for stain-
ing of 51 to 75%, and 4 for staining > 75% of the cells
examined. Intensity was graded as following: 0, no sig-
nal; 1, weak; 2, moderate; and 3, strong staining. A total
score (R × I) of 0 to 12 was finally calculated and graded
as negative (-score: 0-2) and positive (+, 3-12).
Immunofluorescence and laser confocal scanning
After baking on a panel at 60°C for an hour, the sec-
tions were deparaffinized with xylene and rehydrated
through gradient ethanol immersion. This was followed
by a step of antigen retrieval. The slides were immersed
in 0.01 mol/l citrate buffer solution (pH 6.0) and placed
in a microwave oven for 30 min. After a wash in 0.01
mol/l of phosphate-buffered saline (PBS, pH 7.4),
samples were incubated with blocking buffer (5% normal
goat serum, 1% bovine serum albumin and 0.1% triton
X-100) for one hour at room temperature. Samples were
then incubated with primary antibodies diluted in the
blocking buffer at 4°C overnight, followed by 3 washes
in PBS for 10 minutes each. Finally, samples were
stained with secondary antibodies diluted in blocking
buffer for 30 minutes followed by 3 washes in PBS. Cov-
erslips were mounted on slides with Prolong Antifade
(Invitrogen). Antibodies used for immunostaining
include mouse anti-CEACAM7 (1:100, ab26281,
Abcam), rabbit anti-CEA (1:10, ab-15157, Abcam), sec-
ondary antibodies used were goat anti-mouse IgG Alexa
549 (1:300, Invitrogen), goat anti-rabbit IgG Alexa 488
(1:300, Invitrogen), DAPI (1:1000, Molecular Probes).
Adjacent normal tissues were used as negative controls
(20 mm away from the cancer tissue). Immunostained
tissues were visualized and images were captured by
using FlUOVIEW (FVLIOi, OLYMPUS.
Statistical Analysis
All statistical analyses were performed using IBM SPSS
19.0 software. Measurement data were analyzed using Stu-
dent’s t or one-way ANOVA test, while categorical data
were studied using thec2 or nonparametric test. Survival
curves were estimated using the Kaplan-Meier method,
and the log-rank test was used to calculate differences
between the curves. Multivariate analysis using the Cox
proportional hazards regression model was performed to
assess the prognostic values of protein expression. Correla-
tion coefficient between expression of CEACAM7 and
CEA was estimated using the Spearman correlation
method. Statistical significance was set at P < 0.05.
Results
Co-expression of CEACAM7 and CEA in gastric carcinoma
Immunohistochemistry was performed on consecutive
sections of 145 gastric carcinomas using either anti-
CEACAM7 or anti-CEA antibody (Figure 1). Immuno-
histochemical analysis shows that 100 of 145 (69.0%)
samples were categorized as CEACAM7-negative (Figure
1A), and 45 of 145 (31.0%) samples were categorized as
CEACAM7-positive (Figure 1C, 1E). CEACAM7 expres-
sion was concordant with CEA expression in 80.0% (116
of 145) of gastric carcinoma cases (Spearman R = 0.605,
P < 0.001). CEACAM7 and CEA double-positivity was
observed in 40 cases, double-negativity was observed in
76 cases, and 29 cases were found to be either CEA-
CAM7-positive or CEA-positive only. The expression
correlation coefficient was estimated using the Spear-
man Rank Correlation method. The Spearman R value
was 0.605 (P < 0.001), indicating a close correlation
between CEACAM7 and CEA expression in gastric car-
cinomas. As it is inconvenient and unnecessary to check
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cence in all the 40 carcinoma tissues that are positive
for both CEACAM7 and CEA, we investigated their
localization in seven tissue sections that were randomly
selected from the 40 carcinoma tissues sections. Laser
confocal microscopy analysis showed that they co-loca-
lized in the membrane and cytoplasm of cancerous cells
(Figure 2A,B,C,D).
Correlation of CEACAM7 and CEA expression with
clinicopathological features of gastric carcinoma
Relationship between CEACAM7 and CEA expression
and various clinicopathological features of gastric carci-
nomas is summarized in Table 1. CEACAM7 was more
frequently expressed in poorly differentiated tumors than
in well and moderately differentiated gastric carcinomas
(41.3% vs. 20.0%, P = 0.006). CEACAM7 positivity was
significantly higher in diffuse-type gastric carcinomas
than in intestinal-type gastric carcinomas, (39.7% vs.
22.2%, P = 0.023). CEA expression significantly correlated
with lymph node metastasis (P = 0.031).
Dynamic expression of CEACAM7 and CEA in normal
mucosa and precancerous lesions
The results of CEACAM7 and CEA expression in nor-
mal mucosa and precancerous lesions were summar-
ized in Table 2. Positivity for CEACAM7 expression
was found in chronic atrophic gastritis (12%; 6/50),
low-grade GIN (29.1%; 16/55), and high-grade GIN
(28.9%; 13/45). CEACAM7 expression was not found
in normal mucosa (0/50). Positivity for CEACAM7
expression in low grade GINs was significantly higher
than for chronic atrophic gastritis (P = 0.032), and
CEACAM7 was more frequently expressed in atrophic
chronic gastritis than in normal gastric mucosa (P =
0.012), but there was no significant difference in CEA-
CAM7 expression between low-grade GIN and high-
grade GIN (P = 0.982). CEA positivity was found in
normal mucosa (6%; 3/50), chronic atrophic gastritis
(8%; 4/50), low-grade GIN (57.1%; 13/55), and high-
grade GIN (60%; 20/45). The CEA positivity for low-
grade GIN was significantly higher than for chronic
atrophic gastritis (P = 0.030), but was lower than that
for high grade GIN (P = 0.028). There was no signifi-
cant difference in CEA positivity between normal
mucosa and chronic atrophic gastritis (P = 0.500).
CEACAM7 expression was localized to the luminal
surface of chronic atrophic gastritis and GINs (Figure
3C, E, and 3G), no immunoreaction was detected in
normal mucosa (Figure 3A). CEA was localized on the
luminal surface of normal mucosa, chronic atrophic
Figure 1 Co-expression of CEACAM7 and CEA in gastric
carcinomas. A&B, Negative staining for CEACAM7 (A) and CEA (D)
in a well differentiated gastric carcinoma. C&D, CEACAM7 (C) and
CEA (D) staining was negative in the well differentiated area (cancer
cells are ranged in gland-like form) and positive in the poorly
differentiated area (brown color) of a gastric carcinoma. E&F,
Positive staining for CEACAM7 (E) and CEA (F) in a poorly
differentiated gastric carcinoma. A&B, C&D, and E&F are adjacent
serial sections, respectively.(DAB as chromogen, counterstained with
Harris hematoxylin, 50X).
Figure 2 Co-localization of CEACAM7 and CEA in the tissue of
gastric carcinoma (Laser confocal microscopy analysis in a
representative section). Positive expression for CEACAM7 (A, red)
or CEA (B, green) in the membrane and cytoplasm of cancerous
cells (red). C, Merged image without nuclear staining; co-expression
of CEACAM7 and CEA is observed (yellow). D, Merged image with
nucleus stained by DAPI (blue). (200X).
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3B, D, F, and 3H), whereas both CEA and CEACAM7
expression was localized to the entire surface of gastric
cancerous cells (Figure 3I and 3J)
Survival Analysis
One-year and three-year survival rates were 92.0% and
54.1%, respectively, for CEACAM7 and CEA double-
negative patients, 98.3% and 45.1%, respectively, for
Table 1 Correlation of CEACAM 7 and CEA expression with clinicopathological characteristics of gastric carcinoma.
Variables CEACAM 7 P value CEA P value
Negative
(n = 100)
Positive
(n = 45)
Negative
(n = 81)
Positive
(n = 64)
Gender
Male 74(67.3%) 36(32.7%) 0.437 58(52.7%) 52(47.3%) 0.178
Female 26(74.3%) 9 (25.7%) 23(65.7%) 12(34.3%)
Age (Years)
(means ± SD) 59.8 ± 10.4 58.1 ± 13.3 0.608 60.3 ± 9.4 58.9 ± 12.9 0.512
Location of tumor
Upper 12(60.0%) 8 (40.0%) 0.601 9 (45.0%) 11(55.0%) 0.544
Middle 49(69.0%) 22(31.0%) 40(56.3%) 31(43.7%)
Lower 39(72.2%) 15(27.8%) 32(59.3%) 22(40.7%)
Histology †
Well and Moderate 56(80.0%) 14(20.0%) 0.006 43(61.4%) 27(38.6%) 0.741
Undifferentiated 44(58.7%) 31(41.3%) 38(50.7%) 37(49.3%)
Lauren’s classification
Intestinal 56(77.8%) 16(22.2%) 0.023 39(54.2%) 33(45.8%) 0.683
Diffuse 44(60.3%) 29(39.7%) 42(57.5%) 31(42.5%)
Depth of tumor
T1-T2 28(75.7%) 9 (24.3%) 0.307 20(54.1%) 17(45.9%) 0.797
T3-T4 72(66.7%) 36(33.3%) 61(56.5%) 47(43.5%)
Node metastasis
Negative 59(72.8%) 22(27.2%) 0.257 37(67.3%) 18(32.7%) 0.031
Positive 41(64.1%) 23(35.9%) 44(48.9%) 46(51.1%)
Lymphatic invasion
Negative 44(75.9%) 14(24.1%) 0.143 35(60.3%) 23(39.7%) 0.375
Positive 56(64.4%) 31(35.6%) 46(52.9%) 41(47.1%)
Venous invasion
Negative 52(70.3%) 22(29.7%) 0.729 43(58.1%) 31(41.9%) 0.578
Positive 48(67.6%) 23(32.4%) 38(53.5%) 33(46.5%)
Tumor Stage
I- II 40(62.5%) 24(37.5%) 0.135 34(53.1%) 30(46.9%) 0.555
III- IV 60(74.1%) 21(25.9%) 47(58.0%) 34(42.0%)
NOTE: Pearson’s X2 test was done to get P value except that Ages was compared by Student-T test. †Well = well differentiated carcinoma; moderately =
moderately differentiated carcinoma; undifferentiated = poorly differentiated carcinoma, signet ring cell carcinoma, or mucinous carcinoma.
Table 2 Relation between CEACAM7 and CEA expression with different gastric tissues
Tissues N CEACAM7 CEA
Negative Positive P value* Negative Positive P value*
Normal mucosa 50 50 (100%) 0(0%) 0.012
1 47(94%) 3(6%) NS
4
Chronic atrophic gastritis 50 44(88.0%) 6(12.0%) 0.032
2 46(92%) 4(8%) 0.030
5
Low grade GIN 55 39(70.9%) 16(29.1%) NS
3 42(76.4%) 13(23.6%) 0.028
6
High grade GIN 45 32 (71.1%) 13(28.9%) 25(55.6%) 20(44.4%)
*c2 test. N-number of cases, GIN-gastric intraepithelial neoplasia. NS-no significance (P > 0.05).
1 Compared with normal mucosa, CEACAM7 positivity was
significantly higher in chronic atrophic gastritis(P = 0.012);
2 compared with chronic atrophic gastritis, CEACAM7 was more frequently expressed in Low grade
GIN(P = 0.032);
3There was no significant difference of CEACAM7 expression between Low grade GIN and High grade GIN(P = 0.982);
4There was no significant
difference of CEA expression between normal mucosa and chronic atrophic gastritis(P = 0.500);
5Compared with chronic atrophic gastritis, CEA was more
frequently expressed in Low-grade GIN(P = 0.030);
6 Compared with Low grade GIN, CEA was more frequently expressed in High grade GIN (P = 0.028).
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positive or CEA positive) patients, and 64.0% and 8.5%
for CEACAM7 and CEA double-positive patients. Signif-
icant difference was observed between the survival rate
of double-negative and double-positive patients (Figure
4, P = 0.001). However, no significant difference was
found between double-negative and single-positive
patients (Figure 4, P = 0.391). Multivariate analysis
demonstrated that double-positivity for CEACAM7 and
CEA expression (P = 0.004) and tumor stage (P = 0.001)
were factors independently associated with poorer
patient prognosis (Table 3).
Discussion
CEA is one of the most useful tumor markers for carci-
noma[24], and its expression was found to be correlated
with clinicopathological features, such as venous invol-
vement, greater diameter, and advanced stages of color-
ectal carcinomas[25,26]. In colon cancer, CEA is
upregulated, but CEACAM7 was reported to be downre-
gulated[11], it is interesting that they were both upregu-
lated in gastric cancer, and co-expressed in most of the
tissues. suggesting that CEACAM7 may play different
roles in different cancers. As CEACAM7 expression was
found to be closely correlated with CEA expression in
gastric carcinoma in this study, We checked its correla-
tion with various clinicopathological features, and found
that CEACAM7 expression was more frequent in poorly
Figure 3 Different expression patterns of CEACAM7 and CEA in
gastric non-neoplastic lesions and gastric carcinomas.
Consecutive sections were used for analysis. No immunoreaction for
CEACAM7 was detected in normal mucosa (A). CEACAM7 was
localized on the apical surface of chronic atrophic gastritis (C), low
grade GIN (E) and high grade GIN (G). CEA was localized on the
apical luminal surface of normal mucosa (B), chronic atrophic
gastritis (D), low-grade GIN(F), and high-grade GIN (H). Both
CEACAM7 (I) and CEA (J) was localized on the whole surface of
gastric cancerous cells. (DAB as chromogen, counterstained with
Harris hematoxylin, 200X).
Figure 4 Kaplan-Meier curves for postoperative survival.T h e
median survival time of patients with CEACAM7 and CEA double-
positivity was shorter than that of patients with double-negativity
(log-rank test: P = 0.001). But, there was no significant difference
between the median survival time of patients with single-positivity
and double-negativity (P = 0.391).
Table 3 Multivariate analysis based on Cox’s proportional
hazards model
Variable Hazard Ratio (95%
Confidence
Interval)
P-
value
Tumor Stage III, IV vs I, II 2.240 (1.501-3.343) 0.001
CEACAM7(+)CEA(+) vs CEACAM7(-)CEA
(-)
1.545 (1.153-2.069) 0.004
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erately differentiated carcinomas (P = 0.006), and was
also correlated with Lauren’s classification (P = 0.023).
It has been reported that the predominant histologic
type may change from the differentiated to the undiffer-
entiated type as the tumors progress [6], Ohkura, et al
[17] also reported that histologic diversity increases as
gastric carcinomas grow or invade the submucosa. Thus,
we hypothesized that CEACAM7 might promote aggres-
siveness and progression of gastric carcinoma via regu-
lating tumor cell differentiation, and this needs further
investigation.
As intestinal-type cancer is thought to be preceded by
a precancerous stage characterized by the sequential
steps of atrophic gastritis, intestinal metaplasia, GINs,
and intramucosal carcinoma, it would be of great signifi-
cance to clarify the dynamic expression of CEACAM7
and CEA in normal gastric mucosa, chronic atrophic
gastritis, GINs, and gastric carcinoma. We found that,
compared with gastric normal mucosa, CEACAM7
expression was significantly increased in chronic
atrophic gastritis and all other lesions, and CEA expres-
sion was significantly increased in GINs and gastric car-
cinoma. These results indicate that CEACAM7 may play
a role in gastric carcinogenesis from an early stage, spe-
cifically the chronic atrophic gastritis stage. Further-
more, CEA may cooperate with CEACAM7 at the GINs
stage. Consistent with our results, CEA transgenic mice
showed massively enlarged colons comprising a continu-
ous mosaic of severe hyperplasia, dysplasia, and serrated
adenomatous morphology, suggesting that up-regulation
of CEA could be an instrumental step in human cancer
progression [27]. It appears that up-regulation of CEA-
CAM7 or CEA expression may be an early molecular
event in tumorigenesis, and both proteins could be used
as screening biomarkers in precancerous lesions to iden-
tify patients with a high risk of malignant conversion. In
contrast, decreased expression of CEACAM-7 has been
shown to occur early in colorectal oncogenesis, with
decreased expression in adenomas, hyperplastic polyps,
and even aberrant crypt foci.11,13 The contrasting
expression of CEACAM7 in gastric and colorectal carci-
nogenesis implies that its function is context dependent.
Patients with advanced cancer often want to know
h o wl o n gt h e yh a v el e f tt ol i v e[ 2 8 ] ,b u tc l i n i c i a n sa r e
not confident at estimating prognosis [29]. Therefore,
biomarkers for prognosis are a potential tool to help
clinicians with patient care. During the past decade, a
large number of proteins that are putatively important
in carcinogenesis and cancer biology have been studied
for their prognostic value in gastric cancer, but none
have been proven to be sufficiently useful in clinical pre-
diction. It is highly unlikely that a single protein marker
will provide the sensitivity and specificity required for
prognosis. Thus, emphasis has shifted to the discovery
of combinations of biomarkers directly related to disease
processes [30]. In this study, only advanced tumor stage
and CEACAM7 and CEA double-positivity were identi-
fied using the Cox proportional hazards model as inde-
pendent prognostic predictors for the survival of
patients with resectable gastric carcinoma, independent
of age, gender, differentiation, pathologic TNM stage,
lymph node metastasis, lymphatic, and venous invasion
of the patients.
Conclusions
To our knowledge, this is the first comparative immu-
nohistochemical study of CEACAM7 and CEA expres-
sion in gastric carcinoma and precancerous lesions. The
two proteins were co-expressed and co-localized in gas-
tric carcinoma. CEACAM7 expression was found to be
significantly correlated with the differentiation of gastric
carcinoma. The expression of CEACAM7 and CEA was
found to increase gradually during the development of
gastric carcinoma. CEACAM7 and CEA double-positiv-
ity may be a useful postoperative prognostic predictor
for patients with gastric carcinoma.
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